JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

That’s right. Kia has teased the upcoming crossover called the Syros. For now, the Korean manufacturer intends to offer it in ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

caregivers and healthcare professionals who took part in the SELECT-MDS-1 trial and to all the employees of Syros for their exceptional work on the tamibarotene program.” Published first on TheFly – ...

Kia Motors has officially announced its upcoming compact SUV, the Syros, anticipated to hit the global market in the coming weeks with a full launch likely early next year. This model, previously ...

After the launch of EV9 flagship electric SUV and Carnival premium MPV, Kia Syros will be the first SUV to launch under 2.0 ...

The new Kia Syros will soon be unveiled in India. And judging by a local trademark filing, this small boxy SUV could be on ...

As reported by Autocar India, Kia said that the “lounge-like” interior will have “futuristic features and an innovative ...

Kia announces the Syros SUV, the first under its 2.0 strategy in India, blending modern design with advanced technology and ...